Aurora to Participate in the TD Cowen 46th Annual Health Care Conference

NASDAQ | TSX: ACB Canada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market Opportunities EDMONTON, AB, Feb. 17, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.

PRNewsWire • Feb 17, 2026

3 Top Canadian Marijuana Stocks To Buy Sell Or Hold In 2026

What is it about the cannabis industry that keeps investors searching for top marijuana stocks to buy? Cannabis started as one of the first waves of peace, love, and rebellion towards many cultural injustices. Today, those same principles are the foundation in spirit. But the evolution of legal cannabis changed the culture forever. In 2026, significant changes have occurred and continue to happen. We have a battle for who will take over, will it be corporate cannabis or will the true cul;tiovaots be able to take back the industry.

Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 12, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the company will ring the Nasdaq closing bell on Wednesday, February 18, 2026, at the Nasdaq MarketSite in New York's Times Square. The ceremony will be led by Aurora's CEO and Executive Chairman, Miguel Martin, alongside a representative of the company's Board of Directors, executive leadership team and other employees.

PRNewsWire • Feb 12, 2026

Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand

NASDAQ | TSX: ACB Launch reinforces Aurora's leadership position across key international markets  EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

PRNewsWire • Feb 11, 2026

Should You Buy, Hold or Sell ACB Stock Post Q3 Earnings Release?

Aurora Cannabis beat Q3 earnings and sales estimates as medical cannabis momentum drove growth, but persistent consumer weakness pressured the stock outlook.

Zacks Investment Research • Feb 6, 2026

Aurora Cannabis Reports Increased Revenue And Free Cash Flow For Q3-2026

Aurora Cannabis Inc. reported in-line financial results for Q3-2026 with increasing revenue and free cash flow. The company will divest its plant propagation segment and focus on international growth with higher profit margins. The company reported lower revenue for consumer cannabis as it prioritizes its cannabis sales for medical and international markets.

Seeking Alpha • Feb 5, 2026

Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript

Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript

Seeking Alpha • Feb 4, 2026

Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the "ATM Program") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the Company's discretion. The Company intends to use the net proceeds from the Offering for strategic and accretive purposes only, including for increased cultivation capacity and M&A.

PRNewsWire • Feb 4, 2026

Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue 1 Increasing by 12% to a Record $76.2 million Delivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income 1 of $7.2 million Generates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2 EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025. "Aurora has established a commanding leadership position within the rapidly expanding, high margin, global medical cannabis market.

PRNewsWire • Feb 4, 2026

Aurora Launches New European Websites, Showcasing Science-Backed Cannabis Leadership

NASDAQ | TSX: ACB Launch of improved, localized websites underscores Aurora's long-term strategy for growth and engagement across key European medical markets EDMONTON, AB, Feb. 3, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of four brand new websites to support key European markets, continuing its investment in the region through a more focused, locally-relevant digital presence. The refreshed platforms are designed to better reflect Aurora's science-backed approach, manufacturing expertise, and brand strength, while improving engagement with healthcare professionals, partners, and prospective employees across Europe.

PRNewsWire • Feb 3, 2026